You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure

    SBC: Adgero Biopharmaceuticals Holdings Inc            Topic: NHLBI

    Project Summary - Photodynamic Therapy to Prevent Arterio-Venous Fistula Maturation Failure: An Unmet Clinical Need Establishing and maintaining arteriovenous (AV) access sites is critical for patients on hemodialysis. The most preferred AV access is the forearm fistula which is now used for the majority of hemodialysis patients. However, a common problem with AV fistulas is primary maturation fai ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a Nutraceutical Product against Ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Biologically Targeted Vaccine for Chikungunya

    SBC: PRECISION VIROLOGICS INC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. microRNA-21 Blockade of Triple Negative Breast Cancer

    SBC: Bound Therapeutics LLC            Topic: 102

    Triple negative breast cancerTNBCis an orphan disease that attacksUS women every yearTNBC cells lack human estrogen receptorprogesterone receptorand epidermal growth factor receptorHerthe targets of existing medicinesTNBC recurs after standard of care chemotherapy and radiationkilling its victims withinyearsNew promising therapies such as poly ADP ribosepolymerasePARPinhibitors only benefit a smal ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Use of mimotope vaccine technology to develop vaccines against bacterial pathogens

    SBC: ZenVax LLC            Topic: NIAID

    ABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractThere are a number of rare neurodegenerative diseasesincluding Amyotrophic Lateral SclerosisALSand Huntington s DiseaseHDfor which there is no available or effective therapy and which lead to significant morbidity and mortality ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy

    SBC: Medical Guidance Systems LLC            Topic: 102

    Abstract The proposed drug development will result in the design and development of a ligand targeted liposomeLTLthat will aid in the targeted delivery of therapeutics to patients with Non Small Cell Lung CancerNSCLCWe propose an innovative active targeting strategy and our technology exploits the stress response that occurs within the cancer cells following exposure to ionizing radiationThis lipo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Advancement of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)

    SBC: Accuronix Therapeutics Inc            Topic: 102

    Project Summary Abstract Pancreatic cancer is a devastating disease with a very lowyear survival rateTherapeutic options are limited in efficacy and many have substantial toxicityTargeted drug delivery may improve the therapeutic index of cancer drugs by enhancing drug localization to the cancer cell while minimizing off target side effectsreceptors are highly expressed in pancreatic and other can ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Novel insulin-sensitizing NASH/diabetes drugs.

    SBC: BIOIO, LLC            Topic: 300

    Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesityrelated metabolic diseases constitute a significant public health burdenThe increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obeseIn additionobesity is also associated with accumulation of lipid in the liver parenchymahepat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government